Foundayo Before and After: What Results to Expect
The UK prescribing information reports 12.4% average weight loss at 72 weeks in the highest-dose ATTAIN-1 group, compared with 0.9% for placebo. These figures estimate results assuming participants continued treatment; the overall analysis, regardless of treatment adherence, reported 11.2% versus 2.1%. The trial used 36mg capsules, equivalent to the licensed 17.2mg tablet, not interchangeable milligram for milligram. The UK table reports 20.1% achieving at least 20% weight loss. None of these figures guarantees an individual result.
Individual photographs cannot show what result another person will achieve. The ATTAIN-1 study followed adults with obesity, or overweight with a weight-related complication, without diabetes for 72 weeks. All groups received diet and activity support. Our Mounjaro before and after and Wegovy before and after guides explain the evidence for those medicines separately; their results should not be treated as a direct comparison with Foundayo.
Understanding Treatment Timing and Trial ResultsThe First Few Weeks (Titration Begins)
The starting dose is 0.8mg once daily for at least 30 days. This gradual introduction supports tolerability. The timing of appetite changes or visible weight loss varies, and the 72-week trial average cannot predict what you should lose in your first few weeks.
The Middle Titration Period (Months 2–5)
Further dose steps are separated by at least 30 days and depend on the prescribed schedule, response and tolerability. Gastrointestinal symptoms are particularly relevant during dose escalation, although they can also occur at other times. Our Foundayo side effects guide explains common symptoms and when to seek medical help.
Finding the Right Dose
The maximum dose is not a target everyone must reach. Your prescriber reviews response, side effects and interacting medicines before recommending changes. See the Foundayo dosage guide for the licensed schedule. The 72-week ATTAIN-1 endpoint includes the dose-escalation period; it does not establish when an individual will reach their greatest weight loss.
Beyond 72 Weeks
Long-term treatment decisions need an individual review. Foundayo is licensed for weight management, including maintenance, alongside diet and activity. Our Foundayo maintenance guide separates evidence about continuing or switching treatment from what is known about stopping medicines.
| Outcome | UK prescribing-information analysis (highest dose) |
|---|---|
| Achieved 5% or more weight loss | 77.1% |
| Achieved 10% or more weight loss | 59.6% |
| Achieved 20% or more weight loss | 20.1% |
| Placebo group average | 0.9% |
At a starting weight of 100kg, a 12.4% reduction would equal 12.4kg. This is an arithmetic illustration of the trial percentage, not a prediction of your result or a recommended target.
Worth knowing
The figures above come from the UK prescribing-information table at 72 weeks and the analysis estimating outcomes with continued treatment. The published overall treatment-regimen analysis reported a lower average loss of 11.2%, compared with 2.1% on placebo. These analyses answer different questions and should not be mixed when comparing medicines.
ATTAIN-1 also measured waist circumference and cardiometabolic markers. Your prescriber can advise which health measures matter for you. Weight alone does not distinguish fat from lean tissue: our Foundayo muscle loss guide explains the body-composition evidence and practical ways to support strength during treatment.
- Consistency with your titration schedule — reaching and staying at an effective dose matters more than rushing through it
- Diet and lifestyle changes alongside treatment, since Foundayo is licensed to work in combination with a reduced-calorie diet and increased physical activity, not as a standalone solution
- How well you tolerate and manage side effects, since discomfort that leads to skipped doses or early discontinuation limits how much benefit you see
- Your starting weight and individual biology, which affect both the pace and total scale of weight loss achievable for you specifically
- Whether you're using Foundayo for weight management specifically, or as part of managing type 2 diabetes, since the evidence base and expected outcomes differ between these two licensed uses
- Regular reviews of your progress, nutritional intake and treatment tolerability with your prescriber
Results from separate Foundayo, Mounjaro and Wegovy trials are not head-to-head comparisons: populations, doses and analyses differ. Progress can also slow or become uneven. If your weight has stopped changing, the Foundayo weight loss plateau guide explains what to review and when to speak to your prescriber.
Important
Never judge your own progress purely against trial averages, and never increase your dose independently in an attempt to accelerate results. Titration schedules exist for safety reasons, and your prescriber is the right person to discuss your individual progress with, particularly if results feel slower than you expected.
Clinical studies provide group estimates under defined conditions. Everyday outcomes may differ because of treatment interruptions, health conditions and other individual factors. Before-and-after photos and testimonials should not be used to promise a particular outcome.
See What Foundayo® Could Do For You
Check the Foundayo product page for current availability and prices. A free online consultation with our GPhC-registered pharmacy team can help you understand what realistic results might look like for your specific circumstances.
Foundayo pills: availability and prices → Happy Pharmacy is a GPhC-registered pharmacy (No. 9013192) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot